Research Paper Volume 17, Issue 6 pp 1544—1570

Figure 2. KHDC4-mediated adverse prognosis outcomes in prostate cancer are linked to the involvement of TRAF2. (A) A Venn diagram analysis was conducted to gather molecules that are positively or negatively correlated with KHDC4 in TCGA-PRAD datasets, including Cell 2015, Firehose Legacy, and PanCancer Atlas. (B) The graphical abstract illustrates the potential biological roles influenced by KHDC4 in prostate cancer. (C) The canonical pathways influenced by KHDC4-related molecules. (D) Molecular connections associated with KHDC4 regulation in prostate cancer. (E) Volcano plot depicts elevated TRAF2 levels in late-stage TCGA-PRAD patients. (F) The correlation between KHDC4 and TRAF2 in TCGA-PRAD patients. (G) The correlation between KHDC4 and TRAF2 in CCLE prostate cancer cell lines. (H) The related expression intensity of TRAF2 in TCGA-PRAD patients. (I) The difference in the level of TRAF2 between late-stage or lymph node metastasis in TCGA-PRAD patients. (J) The correlation of TRAF2 levels with advanced prostate cancer in different sources of prostate cohorts (GSE21032, GSE35988, GSE6919). (K) Analysis of single-cell sequencing profile (GSE176031) to examine the relative expression levels of KHDC4 and TRAF2 across different cell types. (L) The impact of TRAF2 expression levels on overall survival and disease-free survival rates in prostate cancer.